Luis
Supply Chain at Apellis
Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALSWe challenge conventional thinking and always question if there's a better way.
Join UsPatricia
Quality Assurance at Apellis